Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gallium-68 NOTA-pamidronic acid (also referred to as [68Ga]Ga-NOTA-pamidronic acid) is an investigational gallium-68-labeled bisphosphonate radiotracer developed for positron emission tomography (PET) imaging of the skeleton. It consists of pamidronic acid, a bisphosphonate with high affinity for hydroxyapatite in bone, conjugated to the bifunctional chelator NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) and complexed with the positron-emitting radionuclide gallium-68. Preclinical studies demonstrate that the tracer exhibits favorable skeletal targeting with rapid renal clearance, making it a promising candidate for bone-targeted PET imaging, such as for the detection of bone metastases.
| Indication | Highest phase | Status |
|---|---|---|
| bone metastases | Preclinical | Active |
| bone tumors | Preclinical | Active |
Every indication, with countries and timelines, is in the full profile.
| Market | Status | Year |
|---|---|---|
| United States | Not approved | — |
| European Union | Not approved | — |
| China | Not approved | — |
| Japan | Not approved | — |
Approved indications and other markets are in the full profile.
Lead indication: bone metastases
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gallium-68 NOTA-pamidronic acid.
Work on gallium-68 NOTA-pamidronic acid? Claim this page to correct or add information. Claim this page